| Challenges to curing primary brain tumours K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ... Nature reviews Clinical oncology 16 (8), 509-520, 2019 | 734 | 2019 |
| Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. OV Volpert, WF Ward, MW Lingen, L Chesler, DB Solt, MD Johnson, ... The Journal of clinical investigation 98 (3), 671-679, 1996 | 425 | 1996 |
| The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma T Berry, W Luther, N Bhatnagar, Y Jamin, E Poon, T Sanda, D Pei, ... Cancer cell 22 (1), 117-130, 2012 | 385 | 2012 |
| Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. Y Vodovotz, MS Lucia, KC Flanders, L Chesler, QW Xie, TW Smith, ... The Journal of experimental medicine 184 (4), 1425-1433, 1996 | 383 | 1996 |
| Inhibition of angiogenesis by tissue inhibitor of metalloproteinase MD Johnson, HRC Kim, L Chesler, G Tsao‐Wu, PJ Polverini, N Bouck Journal of cellular physiology 160 (1), 194-202, 1994 | 382 | 1994 |
| Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma M Brockmann, E Poon, T Berry, A Carstensen, HE Deubzer, L Rycak, ... Cancer cell 24 (1), 75-89, 2013 | 332 | 2013 |
| Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma L Chesler, C Schlieve, DD Goldenberg, A Kenney, G Kim, A McMillan, ... Cancer research 66 (16), 8139-8146, 2006 | 245 | 2006 |
| Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC FJ Swartling, V Savov, AI Persson, J Chen, CS Hackett, PA Northcott, ... Cancer cell 21 (5), 601-613, 2012 | 242 | 2012 |
| Pleiotropic role for MYCN in medulloblastoma FJ Swartling, MR Grimmer, CS Hackett, PA Northcott, QW Fan, ... Genes & development 24 (10), 1059-1072, 2010 | 228 | 2010 |
| Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1 L Chesler, DW Golde, N Bersch, MD Johnson | 224 | 1995 |
| Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease RM Hill, S Kuijper, JC Lindsey, K Petrie, EC Schwalbe, K Barker, ... Cancer cell 27 (1), 72-84, 2015 | 217 | 2015 |
| Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma R Zeid, MA Lawlor, E Poon, JM Reyes, M Fulciniti, MA Lopez, TG Scott, ... Nature genetics 50 (4), 515-523, 2018 | 209 | 2018 |
| Regulation of transforming growth factor β1 by nitric oxide Y Vodovotz, L Chesler, H Chong, SJ Kim, JT Simpson, W DeGraff, ... Cancer research 59 (9), 2142-2149, 1999 | 201 | 1999 |
| Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors MW Richards, SG Burgess, E Poon, A Carstensen, M Eilers, L Chesler, ... Proceedings of the National Academy of Sciences 113 (48), 13726-13731, 2016 | 186 | 2016 |
| New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK G Barone, J Anderson, ADJ Pearson, K Petrie, L Chesler Clinical Cancer Research 19 (21), 5814-5821, 2013 | 157 | 2013 |
| Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. Y Vodovotz, AG Geiser, L Chesler, JJ Letterio, A Campbell, MS Lucia, ... The Journal of experimental medicine 183 (5), 2337-2342, 1996 | 151 | 1996 |
| Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium JF Shern, J Selfe, E Izquierdo, R Patidar, HC Chou, YK Song, ME Yohe, ... Journal of Clinical Oncology 39 (26), 2859-2871, 2021 | 138 | 2021 |
| Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity L Fultang, S Booth, O Yogev, B Martins da Costa, V Tubb, S Panetti, ... Blood, The Journal of the American Society of Hematology 136 (10), 1155-1160, 2020 | 117 | 2020 |
| Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity F Mussai, S Egan, S Hunter, H Webber, J Fisher, R Wheat, C McConville, ... Cancer research 75 (15), 3043-3053, 2015 | 111 | 2015 |
| CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs MI Walton, PD Eve, A Hayes, MR Valenti, AK De Haven Brandon, G Box, ... Clinical Cancer Research 18 (20), 5650-5661, 2012 | 106 | 2012 |
Orli Yogev在 cruk.cam.ac.uk 的电子邮件经过验证
